Literature DB >> 19529860

Key enzymes of the extracellular matrix in colorectal cancer.

D A Golovkov1.   

Abstract

The role of extracellular matrix enzymes in the development of distant metastases of colorectal cancer was studied. The expression of types 2 and 9 matrix metalloproteinases was evaluated in primary colorectal adenocarcinomas (264 patients) and their metastases in the lymph nodes (127 patients) and liver (109 patients). Increased expression of matrix metalloproteinase-9 was associated with the probable progress of tumor process and with a low level of histological differentiation of the tumor (p=0.048), deeper invasion of the tumor in the intestinal wall (p=0.012), unfavorable outcome (p=0.037), high risk of metastases in the liver, and worse overall and uneventful survival of patients with colorectal cancer (p=0.001 and p=0.01, respectively). High expression of matrix metalloproteinase-2 was less significant for the invasive potential and prognosis of colorectal tumors. It is suggested that matrix metalloproteinase-9 is an important marker for analysis of the postoperative prognosis and risk of metastases in the liver in patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19529860     DOI: 10.1007/s10517-009-0507-1

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  3 in total

Review 1.  Meeting the biologic challenge of colorectal metastases.

Authors:  Harold J Wanebo; Mark LeGolvan; Philip B Paty; Sukamal Saha; Markus Zuber; Michael I D'Angelica; Nancey E Kemeny
Journal:  Clin Exp Metastasis       Date:  2012-10-10       Impact factor: 5.150

2.  Independent prognostic genes and mechanism investigation for colon cancer.

Authors:  Chunsheng Li; Zhen Shen; Yangyang Zhou; Wei Yu
Journal:  Biol Res       Date:  2018-04-13       Impact factor: 5.612

3.  Identification of a 6-gene signature predicting prognosis for colorectal cancer.

Authors:  Shuguang Zuo; Gongpeng Dai; Xuequn Ren
Journal:  Cancer Cell Int       Date:  2019-01-05       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.